Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference

被引:0
作者
Shan-Fu Yu
Tsong-Shing Yang
Wen-Chan Chiu
Chung-Yuan Hsu
Ching-Lan Chou
Yu-Jih Su
Han-Ming Lai
Ying-Chou Chen
Chung-Jen Chen
Tien-Tsai Cheng
机构
[1] Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine,Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine
[2] Chiayi Chang Gung Memorial Hospital and Chang Gung University College of Medicine,Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine
来源
Journal of Bone and Mineral Metabolism | 2013年 / 31卷
关键词
Osteoporosis; Medication adherence; Risk factors; Pharmacotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Adherence to anti-osteoporotic regimens gradually decreases over time. We hypothesized that the determinants of non-compliance or non-persistence at different times vary and identified these differences. We used an outpatient database to retrieve information on anti-osteoporotic medications prescribed by a medical centre in southern Taiwan during 2001–2007. Compliance was defined as a medication possession ratio (MPR) ≥80 %. Persistence was determined as continuous use, allowing for a refill gap of 30 days. A multivariate Cox regression model evaluated potential predictors of non-adherence. A total of 3589 patients were included. In the multivariate analyses, non-compliance for both year 1 and year 2 was more likely in patients with non-vertebral non-hip fractures, respiratory disorders, prescription of the first anti-osteoporotic regimen by an orthopedist; and less likely in patients with follow-up bone densitometry and switched regimens. Risks for non-persistence at year 1 and year 2 were generally similar to those for non-compliance; insurance coverage and malignancy were associated with a lower risk of non-persistence at year 1 and year 2, respectively. In the subgroup with an MPR ≥80 % at year 1, an index prescription by an orthopedist was the only independent predictor of non-compliance and non-persistence at year 2. In conclusion, the positive or negative determinants of non-adherence were different at year 1 and year 2, which indicated that clinicians might deliver effective interventions to improve adherence via different precautions annually. This study also provided evidence that physician specialty had a significant effect on adherence to osteoporosis care.
引用
收藏
页码:351 / 359
页数:8
相关论文
共 210 条
[1]  
Siris ES(2009)Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3-13
[2]  
Selby PL(2003)Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study Calcif Tissue Int 72 408-1123
[3]  
Saag KG(2004)The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocr Metab 89 1117-968
[4]  
Borgstrom F(2003)Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965-287
[5]  
Herings RM(2004)Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271-1008
[6]  
Silverman SL(2004)The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003-497
[7]  
Eastell R(2005)Adherence to medication N Engl J Med 353 487-55
[8]  
Garnero P(2007)Patient adherence to osteoporosis medications: problems, consequences and management strategies Drugs Aging 24 37-719
[9]  
Vrijens B(2007)Non-compliance: the Achilles’ heel of anti-fracture efficacy Osteoporos Int 18 711-1995
[10]  
Van de Langerijt L(2004)Are there differences between men and women prescribed bisphosphonate therapy in Canadian subspecialty osteoporosis practices? J Rheumatol 31 1993-2419